Prof. Ömer Fatih ÖLMEZ

Publication Network

Journal articles indexed in SCI, SSCI, and AHCI 37

Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes.

Yıldiz A., BİLİCİ A., AÇIKGÖZ Ö., HAMDARD J., BASIM P., ÇAKIR T., et al.

Journal of chemotherapy (Florence, Italy) , vol.37, no.1, pp.60-68, 2025 (SCI-Expanded)

Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer

Tural D., Arslan C., Selcukbiricik F., Ölmez Ö. F., Akar E., Erman M., et al.

Clinical Genitourinary Cancer , vol.22, no.6, 2024 (SCI-Expanded)

Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors

Tural D., Arslan C., Selcukbiricik F., ÖLMEZ Ö. F., ERMAN M., ÜRÜN Y., et al.

Clinical Genitourinary Cancer , vol.22, no.5, 2024 (SCI-Expanded)

Neoadjuvant Pembrolizumab Plus Chemotherapy in Early-Stage Triple-Negative Breast Cancer: A Nationwide Retrospective Turkish Oncology Group Study

Karcı E., Bilici A., Bayram B., Celayir M., Ozyurt N., Oyan Uluç B., et al.

Cancers , vol.16, no.19, 2024 (SCI-Expanded)

Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study

Şenocak Taşçı E., Mutlu A. U., Saylık O., ÖLMEZ Ö. F., BİLİCİ A., Sünger E., et al.

Cancers , vol.16, no.18, 2024 (SCI-Expanded)

Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?

Ocak B., ŞAHİN A. B., Ertürk I., Korkmaz M., Erdem D., Cakıroglu U., et al.

Current Oncology , vol.31, no.9, pp.5195-5205, 2024 (SCI-Expanded)

Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study

KUTLU Y., Dae S. A., YILMAZ F., Erdem D., Sendur M. A. N., Akbas S., et al.

Cancers , vol.16, no.12, 2024 (SCI-Expanded)

Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer

Kutlu Y., Cekin R., Göktaş Aydın S., Shbair A. T. M., Bilici A., Arici S., et al.

CURRENT PROBLEMS IN CANCER , vol.50, 2024 (SCI-Expanded)

A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Kilickap S., Ozturk A., Karadurmus N., Korkmaz T., Yumuk P. F., Çiçin İ., et al.

Medicine , vol.103, no.21, 2024 (SCI-Expanded)

Beyond traditional therapies: clinical significance of complex molecular profiling in patients with advanced solid tumours-results from a Turkish multi-centre study

ÖLMEZ Ö. F., BİLİCİ A., ER Ö., BİŞGİN A., Sevinc A., Akman T., et al.

Japanese journal of clinical oncology , vol.54, no.5, pp.562-568, 2024 (SCI-Expanded)

Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide

Goktas Aydin S., Kutlu Y., Muglu H., Aydin A., Acikgoz Ö., Hamdard J., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , vol.93, pp.71-78, 2024 (SCI-Expanded)

Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

Hamdard J., Bilici A., Sakin A., Kahraman S., Yasin A. I., Kalaci E., et al.

Journal of Chemotherapy , 2024 (SCI-Expanded)

Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study

Taşçı E. Ş., KUTLU Y., ÖLMEZ Ö. F., Mutlu A. U., Gündoğdu Y., Seyyar M., et al.

Expert Opinion on Pharmacotherapy , vol.25, no.4, pp.477-484, 2024 (SCI-Expanded)

Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer

GÖKTAŞ AYDIN S., BİLİCİ A., ÇALIŞ E., KUTLU Y., HAMDARD J., MUĞLU H., et al.

INTERNATIONAL IMMUNOPHARMACOLOGY , vol.124, 2023 (SCI-Expanded)

Major and minor salivary gland cancers: A multicenter retrospective study

Hacioglu M. B., ERDOĞAN B., Bardakcı M., Algın E., Gulbagcı B., Hacibekiroglu I., et al.

Head and Neck , vol.45, no.7, pp.1643-1653, 2023 (SCI-Expanded)

Clinicopathological and Survival Characteristics of Mismatch Repair Status and PD-1 Expression in Serous Ovarian Cancer

Olmez F., Oglak S. C., Akgol S., ÖLMEZ Ö. F., BİLİCİ A., Akbayir O., et al.

Journal of the College of Physicians and Surgeons Pakistan , vol.33, no.6, pp.66-672, 2023 (SCI-Expanded)

Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

Tural D., Arslan C., Selcukbiricik F., ÖLMEZ Ö. F., Akar E., ERMAN M., et al.

Clinical Genitourinary Cancer , vol.21, no.3, pp.334-341, 2023 (SCI-Expanded)

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

Kutlu Y., Aydin S. G., Bilici A., Oven B. B., Ölmez Ö. F., Açıkgöz Ö., et al.

Medicine (United States) , vol.102, no.15, 2023 (SCI-Expanded) Sustainable Development

Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

BİLİCİ A., ÖLMEZ Ö. F., Kaplan M. A., Oksuzoglu B., Sezer A., Karadurmus N., et al.

ACTA ONCOLOGICA , vol.62, no.4, pp.381-390, 2023 (SCI-Expanded) Sustainable Development

Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Erol V. B., GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., AÇIKGÖZ Ö., ÖLMEZ Ö. F., et al.

Journal of Chemotherapy , vol.35, no.7, pp.662-670, 2023 (SCI-Expanded)

Survival outcomes of patients with oligometastatic non-small cell lung cancer who were treated with radical therapy: a multicenter analysis

Acikgoz O., Bilici A., Tataroglu Ozyukseler D., Göktaş Aydın S., Selcukbiricik F., Rzazade R., et al.

Turkish Journal of Medical Sciences , vol.53, no.4, pp.949-961, 2023 (SCI-Expanded)

Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Gürbüz M., KUTLU Y., Akkuş E., KÖKSOY E. B., Köse N., Öven B. B., et al.

Journal of Cancer Research and Clinical Oncology , vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded)

The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer

Aydin S. G., BİLİCİ A., ÖLMEZ Ö. F., Oven B. B., AÇIKGÖZ Ö., ÇAKIR T., et al.

Breast Care , vol.17, no.5, pp.470-479, 2022 (SCI-Expanded)

Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.

GÖKTAŞ AYDIN S., Cakan Demirel B., BİLİCİ A., Topcu A., Aykan M. B., KAHRAMAN S., et al.

Current medical research and opinion , vol.38, no.10, pp.1751-1758, 2022 (SCI-Expanded)

Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma

Tural D., Selçukbiricik F., ÖLMEZ Ö. F., Sümbül A. T., ERMAN M., Coşkun H. Ş., et al.

International Journal of Clinical Oncology , vol.27, no.3, pp.585-591, 2022 (SCI-Expanded)

Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

BİLİCİ A., Uysal M., Menekse S., Akin S., Yildiz F., Turan M., et al.

Cancer Investigation , vol.40, no.2, pp.199-209, 2022 (SCI-Expanded) Sustainable Development

Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer

AÇIKGÖZ Ö., Cakan B., Demir T., BİLİCİ A., Oven B. B., HAMDARD J., et al.

Medicine (United States) , vol.100, no.44, 2021 (SCI-Expanded) Sustainable Development

Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences

Tural D., ÖLMEZ Ö. F., Sümbül A. T., Artaç M., Özhan N., Akar E., et al.

European Urology Focus , vol.7, no.5, pp.1061-1066, 2021 (SCI-Expanded)

Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey

Cakan B., AÇIKGÖZ Ö., BİLİCİ A., Demir T., Oven B. B., HAMDARD J., et al.

Journal of B.U.ON. , vol.26, no.5, pp.1908-1917, 2021 (SCI-Expanded)

Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

Tural D., ÖLMEZ Ö. F., Sümbül A. T., Özhan N., Çakar B., Köstek O., et al.

International Journal of Clinical Oncology , vol.26, no.8, pp.1506-1513, 2021 (SCI-Expanded) Sustainable Development

The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study

Akdeniz N., Kaplan M. A., Uncu D., İNANÇ M., Kaya S., Dane F., et al.

International Journal of Colorectal Disease , vol.36, no.6, pp.1311-1319, 2021 (SCI-Expanded) Sustainable Development

Triple-negative breast cancer presented with metastasis to the heart as first sign of recurrence

BAYRAMGİL A., BİLİCİ A., HAMDARD J., AÇIKGÖZ Ö., ŞEKER M., KILIÇASLAN F., et al.

Breast Journal , vol.27, no.1, pp.56-57, 2021 (SCI-Expanded)

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., Kilickap S., Froesch P., Orlov S., Filippova E., et al.

Lung Cancer , vol.148, pp.48-54, 2020 (SCI-Expanded)

Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade

ÖLMEZ Ö. F., Kinikoglu O., Yilmaz N. H., BİLİCİ A., ÇUBUKÇU E., ŞEKER M., et al.

Journal of Oncology Pharmacy Practice , vol.25, no.6, pp.1526-1530, 2019 (SCI-Expanded) Sustainable Development

Prognostic Significance of Metastatic Lymph Node Ratio in Patients with pN3 Gastric Cancer Who Underwent Curative Gastrectomy

BİLİCİ A., Selcukbiricik F., ŞEKER M., Oven B. B., ÖLMEZ Ö. F., YILDIZ Ö., et al.

Oncology Research and Treatment , vol.42, no.4, pp.204-211, 2019 (SCI-Expanded) Sustainable Development

Association and Prognostic Significance of the Functional −1562C/T Polymorphism in the Promoter Region of MMP-9 in Turkish Patients with Gastric Cancer

Avcı N., Ture M., DELİGÖNÜL A., ÇUBUKÇU E., ÖLMEZ Ö. F., ŞAHİNTÜRK S., et al.

Pathology and Oncology Research , vol.21, no.4, pp.1243-1247, 2015 (SCI-Expanded) Sustainable Development

Prognostic impact of tumor lymphocytic infiltrates in patients with breast cancer undergoing neoadjuvant chemotherapy

Avci N., DELİGÖNÜL A., TOLUNAY Ş., ÇUBUKÇU E., ÖLMEZ Ö. F., Altmisdortoglu O., et al.

Journal of B.U.ON. , vol.20, no.4, pp.994-1000, 2015 (SCI-Expanded)

Articles Published in Other Journals 13

The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.

Göktaş Aydın S., Ölmez Ö. F., Selvi O., Geredeli C., Özden F., Bilici A., et al.

Journal of gastrointestinal cancer , vol.55, no.1, pp.227-236, 2024 (ESCI)

THE IMPORTANCE OF CLINICAL AND LABORATORY PARAMETERS OF BONE MARROW METASTASIS IN PATIENTS WITH SOLID MALIGNANCY-SINGLE CENTER EXPERIENCE

Sadri S., J., Beköz H. S., Cakir A., ÖLMEZ Ö. F., Bilici A.

Karya Journal of Health Science , vol.4, no.3, pp.187-191, 2023 (Peer-Reviewed Journal)

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Aydın S. G., Kavak E. E., Topcu A., Bayramgil A., Akgul F., Kahraman S., et al.

Biomolecules and Biomedicine , vol.23, no.6, pp.1089-1095, 2023 (Scopus)

Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib

ÖLMEZ Ö. F., BİLİCİ A., Gursoy P., ÇUBUKÇU E., Sakin A., KORKMAZ T., et al.

Pulmonology , vol.29, no.6, pp.478-485, 2023 (Scopus) Sustainable Development

The Efficacy And Safety of CDK 4/6 Inhibitors Plus Endocrine Therapy With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2- Negative Metastatic Breast Cancer Patients

acikgoz o., Göktaş Aydın S., Bilici A., Kutlu Y., Muglu H., Karcı E., et al.

ACTA ONCOLOGICA TURCICA , vol.56, no.2, pp.153-160, 2023 (Peer-Reviewed Journal)

SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT

Aydın S., Kutlu Y., Muglu H., Açıkgöz Ö., Aydın A., Bilici A., et al.

İstanbul Tıp Fakültesi Dergisi , vol.86, no.2, pp.117-122, 2023 (ESCI)

The Prevalence of Drug-Drug Interactions and Reported Therapy Related Side-Effects in Oncology Out-Patients

Umar R. M., Ay Z. Y., Güven E., KARATAŞ KOÇBERBER E., ÖLMEZ Ö. F.

CLINICAL AND EXPERIMENTAL HEALTH SCIENCES , vol.13, no.1, pp.212-217, 2023 (Peer-Reviewed Journal)

Treatment Management of Leptomeningeal and Brain Metastases as a First Reccurence Site in a Case with Germ Cell Testicular Tumor

GÖKTAŞ AYDIN S., BİLİCİ A., ÇAKIR A., ÖLMEZ Ö. F., CİLA A., ÜNAL D.

Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi , vol.36, no.1, pp.77-80, 2022 (Peer-Reviewed Journal)

High expression of CD8 in the tumor microenvironment is associated with PD-1 expression and patient survival in high-grade serous ovarian cancer Tümör mikroçevresinde CD8’in yüksek ekspresyonu, yüksek dereceli seröz over kanserinde PD-1 ekspresyonu ve hasta sağkalımı ile ilişkilidir

Ölmez F., Oğlak S. C., ÖLMEZ Ö. F., Akbayır Ö., YILMAZ E., Akgöl S., et al.

Turkish Journal of Obstetrics and Gynecology , vol.19, no.3, pp.246-256, 2022 (Scopus)

Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients with Metastatic Non-Small Cell Lung Cancer

AYDIN S. G., AÇIKGÖZ Ö., KUTLU Y., BİLİCİ A., HAMDARD J., ÖLMEZ Ö. F., et al.

ACTA ONCOLOGICA TURCICA , vol.54, no.3, pp.281-290, 2021 (Peer-Reviewed Journal)

Papilledema: Could it be an important clinical sign of leptomeningeal metastasis? Papilödem: Leptomeninjiyal metastazın önemli klinik işareti olabilir mi?

Düz Ö. A., OLMUŞÇELİK O., Çadırcı F., ÖLMEZ Ö. F.

Haseki Tip Bulteni , vol.58, no.5, pp.441-446, 2020 (ESCI)

Retrospective Evaluation of the Efficacy of Lapatinib Capecitabine in the Treatment of Metastatic Breast Cancer

ÇUBUKÇU E., OCAK B., ÖLMEZ Ö. F., DELİGÖNÜL A., KAÇAN T.

Uludağ Üniversitesi Tıp Fakültesi Dergisi , vol.45, no.1, pp.29-32, 2019 (Peer-Reviewed Journal)

Kanserde Palyatif Tedaviler:Palyatif Kemoterapi Uygulamaları

SAKİN A., ÖLMEZ Ö. F.

Türkiye Klinikleri , vol.3, no.3, pp.261-266, 2017 (Peer-Reviewed Journal)

Papers Presented at Peer-Reviewed Scientific Conferences 6

Are pretreatment inflammation-based prognostic scores useful in predicting the outcomes of patients with ALK-positive NSCLC?

ÖLMEZ Ö. F., BİLİCİ A., GÜRSOY P., ÇUBUKÇU E., YILDIZ O., SAKİN A., et al.

IASLC 2019 World Conference on Lung Cancer, Barcelona, Spain, 7 - 10 September 2019, vol.14, pp.551-552, (Summary Text)

Systemic inflammatory markers as a predictors of response to crizotinib in patients with ALK-positive non-small-cell lung cancer

BİLİCİ A., ÖLMEZ Ö. F., GÜRSOY P., ÇUBUKÇU E., YILDIZ O., SAKİN A., et al.

IASLC 2019 World Conference on Lung Cancer, Barcelona, Spain, 7 - 10 September 2019, vol.14, pp.664-665, (Summary Text)

Özofagus Ca’lı hastada mideye migrate özofajial stentin endoloop yardımı ile çıkarılması.

AKIN M. S., ÖLMEZ Ö. F., CANBALOĞLU ERKAN G., ERSAVAŞ C., SEKİ S., ÇEVİK L.

34. Ulusal Gastroenteroloji Haftası, Antalya, Turkey, 1 - 06 December 2017, pp.263, (Summary Text)

Prognostic significance of positive lymph node ratio in patients with pN3 gastric cancer who underwent curative gastrectomy

BİLİCİ A., ŞEKER M., USTAALİOĞLU BALA B. Ö., ÖLMEZ Ö. F., YILDIZ Ö., ÇAKIR A., et al.

ESMO 19th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 28 June - 01 July 2017, vol.28, pp.35-36, (Summary Text)

İnvaziv Lobüler Meme Karsinomunun Klinik Davranışı ve Metastaz Paterni: 4 Olgunun Değerlendirilmesi

ÇALIŞ E., ÇAKIR A., AKHAN A., SAKA B., ALBAYRAK D., TÜRKMEN İ., et al.

26. Ulusal Patoloji 7. Ulusal Sitopatoloji Kongresi, Antalya, Turkey, 2 - 06 November 2016, (Summary Text)

Epiteloid Rabdomyosarkom: Yeni Tanımlanmış Nadir Bir Antite, Olgu Sunumu

ÇAKIR A., AKHAN A., ORAN G., ÖLMEZ Ö. F., DERVİŞOĞLU S.

25. Ulusal Patoloji Kongresi 6. Sitopatoloji Kongresi, Bursa, Turkey, 14 - 17 October 2015, (Summary Text)

Publications & Works